Concepedia

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Angélica Nogueira‐Rodrigues, Claudio Calazan do Carmo, Célia M. Viégas, Felipe Erlich, C. Camisão, K. Fontão, Roberta de Lima, Daniel Herchenhorn, Renato Martins, G. M. Moralez,

Clinical Cancer Research · 2008 · 48 citations · 25 references

DOI

Abstract

E+CRT is feasible to locally advanced squamous cell cervical cancer and is well tolerated. The maximum tolerated dose has been defined as 150 mg. To the best of our knowledge, this is the first report of a combination of erlotinib, cisplatin, and pelvic radiotherapy.

References

25

Cancer: Principles and Practice of Oncology.

Annals of Internal Medicine · 1991 · 8.5K citations

, , +14

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Peter G. Rose, Brian N. Bundy, E. Blake Watkins et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text

Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer

Mitchell Morris, Patricia J. Eifel, Jiandong Lu et al. · New England Journal of Medicine · 1999 · 2.3K citations

Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix

William A. Peters, P.Y. Liu, Rolland J. Barrett et al. · Journal of Clinical Oncology · 2000 · 2.3K citations · Full text